Compare IRS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
| Metric | IRS | COLL |
|---|---|---|
| Founded | 1943 | 2002 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | IRS | COLL |
|---|---|---|
| Price | $16.65 | $45.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.50 |
| AVG Volume (30 Days) | 133.2K | ★ 449.1K |
| Earning Date | 02-06-2026 | 11-06-2025 |
| Dividend Yield | ★ 8.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.42 | ★ 1.63 |
| Revenue | $359,441,224.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ $3.72 | $28.01 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $10.61 | $23.23 |
| 52 Week High | $17.21 | $50.79 |
| Indicator | IRS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 40.58 |
| Support Level | $15.25 | $48.50 |
| Resistance Level | $16.97 | $50.79 |
| Average True Range (ATR) | 0.56 | 1.27 |
| MACD | 0.11 | -0.66 |
| Stochastic Oscillator | 85.81 | 7.25 |
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.